TC BIOPHARM (HOLDINGS) PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.23 USD | -15.17% |
|
-13.99% | -61.20% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 3.84M 4.8M | Sales 2023 | - | Capitalization | 1.35M 1.69M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.25M | Net income 2023 | -5M -6.24M | EV / Sales 2022 | 0.26 x |
| Net cash position 2022 | 2.01M 2.51M | Net cash position 2023 | 661K 826K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.57
x | P/E ratio 2023 |
-0.13
x | Employees | 41 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.24% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -15.17% | ||
| 1 week | -13.99% | ||
| Current month | -13.99% | ||
| 1 month | -35.26% | ||
| 3 months | +30.73% | ||
| 6 months | -88.39% | ||
| Current year | -61.20% |
1 week
1.06
3.00
1 month
1.063.00
Current year
0.853.35
1 year
0.8520.40
3 years
0.853 500.00
5 years
0.853 500.00
10 years
0.853 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bryan Kobel
CEO | Chief Executive Officer | 44 | 21-05-31 |
Martin Thorp
DFI | Director of Finance/CFO | 72 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Bonyhadi
BRD | Director/Board Member | 70 | 22-02-21 |
Martin Thorp
DFI | Director of Finance/CFO | 72 | 14-12-31 |
Arlene Morris
CHM | Chairman | 72 | 22-02-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 1.23 | -15.17% | 6,491,715 |
| 24-05-06 | 1.45 | -0.68% | 41,453,253 |
| 24-05-03 | 1.46 | +0.69% | 45,370 |
| 24-05-02 | 1.45 | -2.03% | 45,792 |
| 24-05-01 | 1.48 | +3.50% | 52,160 |
End-of-day quote Nasdaq, May 06, 2024
More quotes
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Companyâs pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
| 1st Jan change | Capi. | |
|---|---|---|
| -61.20% | 4.63M | |
| +21.74% | 46.81B | |
| -0.97% | 41.37B | |
| +47.07% | 41.29B | |
| -3.52% | 28.87B | |
| +11.12% | 26.06B | |
| -19.37% | 19.13B | |
| +31.18% | 12.39B | |
| -0.04% | 12.08B | |
| +0.39% | 11.96B |
- Stock Market
- Equities
- TCBP Stock